(JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib cream for topical use in dermatological indications worldwide ...

In good news for patients living with chronic hand eczema (CHE), Leo Pharma – a company working ... topline results for its delgocitinib cream treatment, an investigational topical pan-Janus ...

1 The publication summarizes the results of DELTA FORCE, a phase 3, two-arm trial (N=513) that compares the efficacy and safety of delgocitinib cream with ... for the LEO Pharma team," said ...

1 LEO Pharma A/S, a global leader in medical dermatology ... of the DELTA FORCE trial for investigational delgocitinib cream. The publication summarizes the results of DELTA FORCE, a phase ...

Dermatology specialist LEO Pharma has built the case for its first ... for the condition in a phase 3 trial. LEO’s topical cream formulation of the pan-JAK inhibitor proved to be more effective ...

In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib cream for topical use in ...

according to the second phase of the survey sponsored by LEO Pharma Inc., a global leader in medical dermatology, and conducted by Ipsos. The survey, which includes responses from 100 doctors and ...

More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with ... from eczema—though Leo’s delgocitinib cream, a topical JAK inhibitor dubbed Anzupgo, is currently ...

LEO Pharma A/S, a global leader in medical dermatology ... of the DELTA FORCE trial for investigational delgocitinib cream.

LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline results of the phase 2b trial with temtokibart, an investigational IL-22RA1 antagonist, for the potential ...